Literature DB >> 29358781

Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy.

Grant Otto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29358781     DOI： 10.1038/nrclinonc.2018.12

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Authors:  Diana Miao; Claire A Margolis; Wenhua Gao; Martin H Voss; Wei Li; Dylan J Martini; Craig Norton; Dominick Bossé; Stephanie M Wankowicz; Dana Cullen; Christine Horak; Megan Wind-Rotolo; Adam Tracy; Marios Giannakis; Frank Stephen Hodi; Charles G Drake; Mark W Ball; Mohamad E Allaf; Alexandra Snyder; Matthew D Hellmann; Thai Ho; Robert J Motzer; Sabina Signoretti; William G Kaelin; Toni K Choueiri; Eliezer M Van Allen
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728
  1 in total
  4 in total

Review 1.  Review of precision cancer medicine: Evolution of the treatment paradigm.

Authors:  Apostolia M Tsimberidou; Elena Fountzilas; Mina Nikanjam; Razelle Kurzrock
Journal:  Cancer Treat Rev       Date:  2020-03-31       Impact factor: 12.111

2.  Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.

Authors:  Minghao Sui; Yu Li; Hongguang Wang; Ying Luo; Tao Wan; Xun Wang; Bingyang Hu; Yanshuang Cheng; Xianrong Lv; Xianlei Xin; Qiang Xu; Guan Wang; Shichun Lu
Journal:  J Immunother Cancer       Date:  2019-05-07       Impact factor: 13.751

3.  Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients.

Authors:  Amin Haghighat Jahromi; Donald A Barkauskas; Matthew Zabel; Aaron M Goodman; Garret Frampton; Mina Nikanjam; Carl K Hoh; Razelle Kurzrock
Journal:  EJNMMI Res       Date:  2020-12-09       Impact factor: 3.138

4.  Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.

Authors:  Toshiaki Akahane; Naoki Kanomata; Oi Harada; Tetsumasa Yamashita; Junichi Kurebayashi; Akihide Tanimoto; Takuya Moriya
Journal:  BMC Cancer       Date:  2020-10-01       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.